Developing drugs for developing countries

Health Affairs
David B RidleyJeffrey L Moe

Abstract

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments for neglected diseases receive a "priority review voucher." The voucher could save an average of one year of U.S. Food and Drug Administration (FDA) review and be sold by the developer to the manufacturer of a blockbuster drug. In a well-functioning market, the voucher would speed access to highly valued treatments. Thus, the voucher could benefit consumers in both developing and developed countries at relatively low cost to the taxpayer.

References

Mar 16, 2000·Health Affairs·P J NeumannR H Chapman
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Mar 26, 2004·Nature Reviews. Drug Discovery·Hannah E Kettler, Sonja Marjanovic
Jun 8, 2004·The Journal of Economic Perspectives : a Journal of the American Economic Association·Michael Kremer
Nov 24, 2004·Journal of Health Economics·Mary K Olson
May 12, 2005·Health Affairs·Ernst R Berndt, John A Hurvitz
May 12, 2005·Health Affairs·Henry Grabowski
Jul 5, 2005·BMJ : British Medical Journal·Rhona MacDonald
Jul 30, 2005·Nature Reviews. Drug Discovery·Ernst R BerndtMatthew W Strobeck
Sep 24, 2005·Science·John P WalshWesley M Cohen
Mar 9, 2006·Health Affairs·David B RidleyKevin A Schulman

❮ Previous
Next ❯

Citations

Jun 28, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Fernando AntoñanzasRoberto Rodríguez-Ibeas
Aug 4, 2012·Lancet·Peter HowittElizabeth Wilson
Sep 10, 2008·Nature Biotechnology·Jason MathenyBradley Smith
Dec 9, 2008·Nature Biotechnology·Emily Waltz
Feb 9, 2012·Nature Medicine·Roxanne Palmer
Feb 21, 2009·The New England Journal of Medicine·Jeffrey MoeDavid Ridley
Nov 5, 2010·The New England Journal of Medicine·Aaron S Kesselheim
Nov 7, 2008·The New England Journal of Medicine·Aaron S Kesselheim
Jan 21, 2011·Science Translational Medicine·Edward Connor, Pablo Cure
Sep 7, 2012·PLoS Neglected Tropical Diseases·Andrew S RobertsonMelinda Moree
Aug 21, 2007·Paediatric Drugs·Stuart MacLeodJane Schaller
Nov 16, 2010·Future Microbiology·Timothy M E DavisStephen J Rogerson
Jun 8, 2014·Clinical Therapeutics·Joshua P CohenAlisa Cohen
Jun 18, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Fernando AntoñanzasCarmelo A Juárez-Castelló
Sep 12, 2015·Annual Review of Medicine·Peter J HotezUlrich Strych
Mar 22, 2008·Health Services Research·Margaret K KyleKevin A Schulman
Apr 26, 2008·The International Journal of Health Planning and Management·Stefano VillaMichael R Reich
Dec 9, 2008·American Heart Journal·Robert M CaliffKevin A Schulman
Sep 9, 2015·The American Economic Review·Eric BudishHeidi Williams
Mar 29, 2011·Journal of the International AIDS Society·Ellen 't HoenSuerie Moon
May 20, 2009·Clinical Pharmacology and Therapeutics·J MathenyM Mair
Aug 26, 2014·Annual Review of Pharmacology and Toxicology·Sara Parker-LueGreg Koski
Oct 4, 2016·International Journal for Parasitology. Drugs and Drug Resistance·Annette C Kuesel
Apr 9, 2009·Nature Biotechnology·Joanna E Lowell, Christopher D Earl
Sep 10, 2014·Health Affairs·Ernst R Berndt, Iain M Cockburn
May 4, 2016·Health Affairs·David B Ridley, Stephane A Régnier
Sep 13, 2007·Health Affairs·Margaret K Kyle, David B Ridley
Nov 6, 2009·Health Affairs·Philip Musgrove, Peter J Hotez
Aug 10, 2018·PLoS Neglected Tropical Diseases·Kirk W KerrKathleen L Miller
Dec 19, 2015·Canadian Journal of Public Health = Revue Canadienne De Santé Publique·Steven J Hoffman, Sarah L Silverberg
Oct 24, 2007·Clinical Pharmacology and Therapeutics·J A DiMasi, H G Grabowski
Dec 17, 2014·BMC Medical Informatics and Decision Making·Senafekesh BirukBinyam Tilahun
Sep 11, 2010·Nature Biotechnology·Rahim Rezaie, Peter A Singer
Jul 9, 2016·Nature Medicine
Nov 29, 2017·Healthcare Informatics Research·Sai Wai Yan Myint ThuWirichada Pan-Ngum
Aug 7, 2013·Clinical Pharmacology and Therapeutics·C-P Milne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiparasitics

Antiparasitics are medications which are indicated for the treatment of parasitic diseases. Discover the latest research on antiparasitics here.